On this page
Identify the study before using the claim
A 2016 PLOS ONE paper investigated Corydalis yanhusuo extract in mouse models of acute, inflammatory and neuropathic pain. It also examined dopamine-receptor mechanisms. Those experiments concern a defined research extract in animals, not this marketed capsule. PLOS ONE: The Antinociceptive Properties of the Corydalis yanhusuo Extract (2016).
The missing steps in the comparison
| Study feature | Product question |
|---|---|
| Research extract | Is the marketed ingredient the same preparation? |
| Animal dose and administration | Has a relevant human regimen been tested? |
| Experimental pain outcomes | Were patient-important outcomes measured in people? |
| Controlled experimental conditions | Does the evidence extend to a mixed formula and real-world users? |
Do not translate a mouse dose into a self-selected supplement dose. That requires scientific and clinical work beyond dividing numbers by body weight.
How a claim can become overstated
An accurate statement is that the experiment investigated an extract in animals. An unsupported leap would be that a bottle containing a named plant therefore repairs nerves or has been proven to relieve a buyer’s neuropathy. The missing link is not solved by adding the university name beside the claim.
A primary paper is valuable because its methods show the boundaries. Reading the methods can make a marketing conclusion narrower rather than stronger.
What would improve confidence?
- A current label matching the ingredient to the preparation.
- Appropriate human studies using a documented formula and dose.
- Outcomes relevant to the claimed benefit.
- Reported adverse events and adequate follow-up.
Until those questions are answered, keep the conclusion at the level of research interest. See the overall evidence assessment for the same reasoning applied to the finished product.